Paper · 8097319
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff G and 9 others. Proc Natl Acad Sci U S A, 1993. Cited by 2,585 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Papers, record 8097319. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8097319
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
- PubMed
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Renal Cell | Major topic |
| Colonic Neoplasms | Major topic |
| Fibrosarcoma | Major topic |
| Granulocyte-Macrophage Colony-Stimulating Factor | Major topic |
| Immunization | Major topic |
| Kidney Neoplasms | Major topic |
| Lung Neoplasms | Major topic |
| Melanoma, Experimental | Major topic |
| Transfection | Major topic |
| Animals | |
| Antibodies, Monoclonal | |
| CD4 Antigens | |
| CD8 Antigens | |
| Cell Adhesion Molecules | |
| Female | |
| Genetic Vectors | |
| Intercellular Adhesion Molecule-1 | |
| Lymphocyte Depletion | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Inbred C57BL | |
| Retroviridae | |
| T-Lymphocyte Subsets | |
| Tumor Cells, Cultured |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1,109,790 | Biological behavior of malignant melanoma cells correlated to their survival in vivo. | Cancer Res | 1975 | https://conductscience.org/library/papers/1109790 | PubMed |
| 2 | 13,756,652 | Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. | Cancer Res | 1960 | https://conductscience.org/library/papers/13756652 | PubMed |
| 3 | 6,310,596 | Cloning and expression of murine immune interferon cDNA. | Proc Natl Acad Sci U S A | 1983 | https://conductscience.org/library/papers/6310596 | PubMed |
| 4 | 6,415,170 | Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. | J Immunol | 1983 | https://conductscience.org/library/papers/6415170 | PubMed |
| 5 | 2,981,916 | Inhibition of mixed lymphocyte response by a rat monoclonal antibody to a novel murine lymphocyte activation antigen (MALA-2). | J Immunol | 1985 | https://conductscience.org/library/papers/2981916 | PubMed |
| 6 | 3,918,306 | Use of a cDNA expression vector for isolation of mouse interleukin 2 cDNA clones: expression of T-cell growth-factor activity after transfection of monkey cells. | Proc Natl Acad Sci U S A | 1985 | https://conductscience.org/library/papers/3918306 | PubMed |
| 7 | 3,856,324 | Molecular cloning of the complementary DNA for human tumor necrosis factor. | Science | 1985 | https://conductscience.org/library/papers/3856324 | PubMed |
| 8 | 3,874,057 | Structure and expression of the mRNA for murine granulocyte-macrophage colony stimulating factor. | EMBO J | 1985 | https://conductscience.org/library/papers/3874057 | PubMed |
| 9 | 3,083,412 | Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities. | Proc Natl Acad Sci U S A | 1986 | https://conductscience.org/library/papers/3083412 | PubMed |
| 10 | 3,782,794 | The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. | J Immunol | 1986 | https://conductscience.org/library/papers/3782794 | PubMed |
1 to 10 of 34
See all 34 referencesCited by868
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,585 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,620,938 | A review of soluble mediator and cytokine networks linking combination immunotherapy, tumor microenvironment remodeling and skeletal muscle dysfunction. | Front Immunol | 2026 | https://conductscience.org/library/papers/42620938 | PubMed |
| 42,592,303 | Universal off-the-shelf TGF-β1-knockout whole-tumor cell vaccine overcomes immunotherapy resistance in pMMR/MSS tumors. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42592303 | PubMed |
| 42,393,779 | Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/42393779 | PubMed |
| 42,350,605 | Immunological mechanisms and therapeutic advances in chronic myeloid leukemia. | Leukemia | 2026 | https://conductscience.org/library/papers/42350605 | PubMed |
| 42,321,431 | Bacterialized tumor cells as vaccine. | EMBO Mol Med | 2026 | https://conductscience.org/library/papers/42321431 | PubMed |
| 42,188,765 | Needle-Free Injection Enhances the Immunogenicity and Antitumor Efficacy of Whole-Cell Tumor Vaccines. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42188765 | PubMed |
| 42,161,938 | microRNA-25 drives immune checkpoint therapy resistance by repressing innate and humoral immunity via Syndecan-3. | Nat Commun | 2026 | https://conductscience.org/library/papers/42161938 | PubMed |
| 42,146,112 | Endogenous living adjuvants for cancer vaccination: Concepts, mechanisms, and design principles. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42146112 | PubMed |
| 42,099,233 | Radiotherapy and cytokines: A systems view of immunotherapy and toxicity (Review). | Int J Mol Med | 2026 | https://conductscience.org/library/papers/42099233 | PubMed |
| 41,947,668 | Irradiated Liver Cancer Cell Vaccine Transfected With GM-CSF Induces Specific and Long-Lasting Anti-tumour Immunity Through the Synergistic Effect of Oxidised mtDNA and GM-CSF. | Cell Prolif | 2026 | https://conductscience.org/library/papers/41947668 | PubMed |
1 to 10 of 868
See all 868 cited byGenes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8097319
GET https://conductscience.org/api/papers/v1/8097319/references?page=2